Board of Directors

Michelet was appointed Chair of the Board of SpinChip Diagnostics AS in December 2015. Michelet has a long experience from the pharmaceutical industry; Nycomed, Amersham and GE Healthcare. She has held leading positions in these companies within R&D, marketing and manufacturing. Michelet has also been CEO in Marine Harvest ASA (now Mowi ASA) and Teres Medical Group AS. She has held many board positions in Norwegian industrial companies and currently chair the board of CSAM Health Group AS and BI Norwegian Business School. She is a board member in Odfjell SE. Michelet has her education from ETH in Zurich and is Cand. pharm. from the University of Oslo.

Haugdal is an associate at the investment team at Investinor AS, an investment company owned by the Norwegian government. In Investinor Haugdal works with companies within the health sector, including biotech and MedTech. She also works with some of Investinors portfolio companies within the digital platform space. Haugdal holds a master’s degree in business administration and economics from the Norwegian school of economics and is currently in the process of finishing a PhD at the Norwegian University of Science and Technology. Haugdal joined the board of SpinChip in 2023.

Kongsnes is Deputy/Investment Director at Investinor AS. During her 20-year career, Kongsnes has obtained extensive experience in venture capital investments in health and technology enterprises. She has also worked with M&A, IPOs and technology company exits. She currently focuses primarily on new investments and on Investinor’s portfolio companies within the health sector, including biotechs, pharmas, medtech and digital health enterprises. She also works with some of our semiconductor/deep tech companies and sits on the Boards of both listed and private companies. Kongsnes holds an MSc in Economics and Business Administration from the former Bodø Graduate School of Business (HiB), and has completed the Advanced Program in Corporate Finance at the Norwegian School of Economics (NHH). She joined the Board of SpinChip in 2015.

Hadley is a Medical Doctor and the Head of Clinical Development at Age Labs AS, where she works on the development and commercialization of epigenetic tests. She gained her medical degree from the University of Oslo, and has experience in the fields of Cardiology and Internal Medicine through her work at Molde Hospital and Oslo University Hospital. She is experienced in managing clinical multicenter trials and holds a PhD in Acute Medicine. Additionally, she has studied Business and Administration at Oslo Business School. Hadley joined the Board of SpinChip in 2024.

Jesper Melin Ganc-Petersen is a medical doctor and holds a Diploma in Business Administration. Since 1995, Dr. Melin has been involved in remote diagnostics and treatment, initially in telemedicine and m-health, and later in AI-assisted patient engagement and point-of-care solutions. He has served as an officer in both the Danish Army and Navy. Dr. Melin served on active duty in Greenland with the Danish Special Unit, Sirius Patrol, for 3 years. In 2017, Dr. Melin was awarded the EY Entrepreneur of the Year in the service category. Over the past 4-5 years, Dr. Melin has led and managed significant exit processes for various companies. Today, Dr. Melin runs his own family office, primarily focused on healthcare and green tech investments. Dr. Melin joined the Board of SpinChip in 2024.

Öhman was nominated to the board of SpinChip in the fall 2015. Öhman has founded or co-founded several companies such as Åmic AB, Fiomi Diagnostics AB, Sigolis AB, Ginolis Oy and Astrego Diagnostics AB. He acts today in several boards but also work with technical development in small startups. He has master degree in Applied Physics and received the Polhem Prize 2003. He was called as honorary doctor at Uppsala University 2005. Öhman is a board member of Astrego Diagnostics AB, Meje AB, Moleculent AB and Rarity Biosciences AB.

Newly appointed to the Board of SpinChip in the spring of 2023, Frei has more than 25 years of experience in the field of In Vitro Diagnostics during which time he has contributed to successfully launching new IVD platforms into the European market. After graduating from the University of Johannesburg as a Biomedical Technologist, Frei has gathered vast experience working in several hospital laboratories and Diagnostic companies in a number of positions including Application Specialist, Product and Sales Manager. Frei is currently a Member of the Executive Board and Business Unit Head of the hospital division at Axon Lab AG.

Lien holds a Master of Science degree in business (Siviløkonom) from the Norwegian School of Management, BI, and has wide experience. From 1990 to 1993, he was a Director of Teknoinvest, a Norwegian venture company. From 1993 he was appointed President of Axis Biochemicals ASA. He became Joint Managing Director of Axis-Shield plc when Axis Biochemicals ASA merged with Shield Diagnostics Group plc in May 1999 and was later appointed Chief Executive Officer for the Group.  He stepped down from this role at year end 2007 and became Partner in Cubera Private Equity from spring 2008 until autumn 2009.  He then spent time building up his own consultancy and advisory business before taking over as CEO of Biotec Pharmacon ASA from March 2010 to end 2017. Since then he has spent time consultancy e.g. lately as working Chairman and Managing Director at Havyard Ship Technologies when it went through a successful Compulsory Composition. Lien has been involved in a number of other hightech companies mostly in life science and still holds a few Board positions. He joined the Board of SpinChip in 2020.

Morgeau is representing bioMérieux, a global leader of In Vitro Diagnostics specialized in infectious disease and critical care, which is a minority shareholder of Spinchip. At bioMérieux, he is heading Strategy and is acting as Secretary of the Executive Committee. Morgeau holds an engineering degree in Biochemistry from the Institut National des Sciences Appliquées of Toulouse and a MBA in Innovation Management from the University of Toulouse. He started his career in strategic consulting, working with all leaders of Life Sciences (pharmaceuticals, diagnostics, Medtechs) and then joined bioMérieux in 2011 where he held several position in financial controlling, budget process owner and investor relations. Morgeau joined the board of SpinChip in 2024 as an observer.